Early Effects of Transplatin on Oncogene Activation In Vivo

• Published in: Anticancer research Vol. 24; no. 6; pp. 3997 - 4001
• Main Authors: NEMETH, A, NADASI, E, EMBER, I, BERO, A, OLASZ, L, EMBER, A, KVARDA, A, BUJDOSO, L, ARANY, I, CSEJTEI, A, FALUHELYI, Zs
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.11.2004
• Subjects: Animals; Biological and medical sciences; Cisplatin - pharmacology; Female; Gene Expression Regulation - drug effects; Genes, myc - drug effects; Genes, myc - genetics; Genes, p53 - drug effects; Genes, p53 - genetics; Genes, ras - drug effects; Genes, ras - genetics; Kidney - drug effects; Kidney - physiology; Liver - drug effects; Liver - physiology; Lung - drug effects; Lung - physiology; Medical sciences; Mice; Mice, Inbred CBA; Spleen - drug effects; Spleen - physiology; Tumors; In vivo; Head and neck cancer; platinum isomers; Cancerology; oncogene expression; Onc gene
• ISSN: 0250-7005; 1791-7530

The aim of the study was to investigate the early effect of Transplatin (the stereo-isomer of Cisplatin) on oncogenes in inbred CBA/Ca mice. Cisplatin is commonly used for the treatment of squamous cell carcinomas of the head and neck. Cisplatin has a strong oncogene activation effect compared to the structural analogue Transplatin. Body weight equivalent amounts of a human dose of Transplatin were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the expressions of c-myc, Haras and p53 genes were examined. Investigation of early changes showed no significant overexpression compared to Cisplatin, which had a significant effect on oncogene expression in the “short-term” in vivo test system.